ImmunoGenesis is a clinical-stage biotechnology company developing therapeutics to provide more consistent benefit to patients with immune-infiltrated tumors and for the first time catalyze effective immune responses in immunologically “cold†cancers such as prostate, colorectal and pancreatic cancer. These tumor types represent more than half of all cancers, and current immunotherapies have shown limited to no efficacy here. As a result, there is a high unmet need and substantial market opportunity for efficacious therapies.